Disease Landscape Analysis 2026
Drug pipelines, approved treatments and market analysis for every major disease — updated daily from primary regulatory + scientific sources.
12+ therapeutic areas
520K+ clinical trials indexed
156K+ drugs tracked
Daily data refresh
Browse by therapeutic area
Other4921 drugsOncology4167 drugsCardiovascular1906 drugsImmunology1702 drugsInfectious Disease1413 drugsDiabetes1069 drugsNeuroscience762 drugsMetabolic676 drugsOphthalmology655 drugsDermatology634 drugsImmunology / Infectious Disease631 drugsNeurology510 drugs
What's in a disease landscape report?
- Approved drugs — every FDA, EMA, PMDA and MHRA-approved therapy with indications, mechanism, manufacturer and revenue.
- Pipeline by phase — Phase 1 / 2 / 3 candidates, primary endpoints, expected readout dates.
- Treatment pathways — first-line, second-line and salvage therapy with guideline recommendations from NCCN, ESMO, NICE, ICER and KDIGO.
- Competitive crowding — sponsors active in the space, late-stage assets, patent expiries, generic/biosimilar entry timing.
- Real-world data — peer-reviewed publications, KOL commentary, FDA AdCom transcripts.
How it's used
Biotech analysts use the disease landscape to size addressable markets, identify under-priced catalysts, and time long/short trades around clinical readouts. Pharma BD teams use it for target screening, competitive intelligence, and deal diligence. Consultants use it as the structured fact base behind every client engagement on a given indication.